Merck Investors Have Reason to Cheer This Label Expansion

Submitted by admin on September 9, 2021 - 10:54am

Source:

Motley Fool

News Tags:

Headline:

snippet:

Japan's PDMA approved Keytruda in combination with chemotherapy to treat triple-negative breast cancer.
With an addressable market of tens of thousands of patients, this indication could bring in a few hundred million dollars in annual revenue.
Merck's dividend has plenty of room to grow when considering the company's strong oncology, vaccines, and animal health segments.

Search form